Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For the prospective group (joining the trial going forward):

• People who give signed and dated consent within 28 days of starting ribociclib combined with aromatase inhibitor therapy (with or without GnRH agonist medications)
• People aged 18 or older at the time of signing the consent form
• People who have been diagnosed through laboratory testing with hormone receptor-positive, HER2-negative stage II or III breast cancer that has been treated with the goal of removing the disease completely
• People whose hormone therapy with aromatase inhibitors (with or without GnRH agonists) was started no more than 12 months before beginning ribociclib treatment
• People with a general health and activity level rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity — confirm with trial site)

For the retrospective group (based on past treatment records):

• People aged 18 or older when hormone therapy began
• People who have been diagnosed through laboratory testing with hormone receptor-positive, HER2-negative stage II or III breast cancer that has been treated with the goal of removing the disease completely
• People who started adjuvant hormone therapy with aromatase inhibitors (with or without GnRH agonists) between 1 July 2019 and 1 July 2020
• People whose medical records contain all the necessary information required for the study

Who may not be able to join:

For the prospective group:

• People who have previously been treated with abemaciclib or palbociclib (similar medications to ribociclib)
• People who have already been taking ribociclib combined with an aromatase inhibitor for more than 28 days at the time of signing the consent form
• People currently receiving treatment for another cancer
• People currently participating in another interventional clinical trial at the time of signing the consent form

For the retrospective group:

• People who received CDK4/6 inhibitor medications (a class of cancer drugs) either before or after surgery as part of their breast cancer treatment
• People with a history of another cancer that required active treatment at the same time
• People who were participating in another interventional clinical trial during their breast cancer treatment
• Note: People whose breast cancer returned during hormone therapy may still be considered if they meet the other criteria listed above (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.